Institut Curie - Site de Paris

The trials here

What the 4 trials at this site are about, from their registry records.

Conditions

• Metastatic breast cancer3 trials
• Cervical cancer1 trial

Phase

• Phase 32 trials

Status

• Completed2 trials
• Active, not recruiting1 trial
• Withdrawn1 trial

Lead sponsor

• Daiichi Sankyo2 trials
• Centre Hospitalier Universitaire de Besancon1 trial
• Institut Claudius Regaud1 trial

Running trials

• Active, not recruiting

  International Validation Study of Sentinel Node Biopsy in Early Cervical Cancer

  NCT03386734· Centre Hospitalier Universitaire de Besancon· Source

Closed trials

• Recruiting

  Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer.

  NCT05378204· Institut Claudius Regaud· Source

  Contact: Florence DALENC

• Completed

  Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

  NCT03734029· Phase 3· Daiichi Sankyo· Source

• Completed

  DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]

  NCT03523585· Phase 3· Daiichi Sankyo· Source